<HashMap><database>biostudies-other</database><scores/><additional><omics_type>Unknown</omics_type><volume>4(3)</volume><submitter>Mitchell RA</submitter><journal>Transplantation direct</journal><pagination>e347</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5912017</full_dataset_link><abstract>The goal of treating chronic hepatitis C virus (HCV) infection is sustained virologic response (SVR). There is concern that despite achieving SVR, replication-competent HCV may be sequestered at low levels within the liver and could theoretically reactivate with immunosuppression. We report transplantation of a HCV-seropositive liver donor, who achieved SVR, into a seronegative patient without HCV reactivation despite profound immunosuppression.Retrospective chart review.We present a 21-year-old male who was HCV seronegative and received a liver transplant from a donor who had been treated for HCV and achieved SVR. The liver recipient, despite developing severe acute graft rejection and undergoing intense immunosuppression with T cell-depleting antibodies, did not become HCV RNA-positive with a follow up period of 8 months. The recipient was HCV seronegative before transplant, but became HCV seropositive immediately posttransplant. The antibodies were undetectable after 97 days, in keeping with a passive antibody transmission or B lymphocyte transmission with the graft.To the best of our knowledge, this is the first reported case of an HCV seropositive liver allograft transplanted into an HCV-negative recipient who subsequently received intense immunosuppression. This case, therefore, is an encouraging and novel step in liver transplantation, and demonstrates that SVR may be closer to a true "cure" of HCV in the donor population and that, even in circumstances of very potent immunosuppression in the recipient, this SVR is sustained.</abstract><repository>biostudies-other</repository><pmcid>PMC5912017</pmcid><data_source>Europe PMC</data_source><pubmed_authors>Yau AH</pubmed_authors><pubmed_authors>Mitchell RA</pubmed_authors><pubmed_authors>Wright AJ</pubmed_authors><pubmed_authors>Scudamore CH</pubmed_authors><pubmed_authors>Marquez Azalgara V</pubmed_authors><pubmed_authors>Yoshida EM</pubmed_authors><pubmed_authors>Hussaini T</pubmed_authors><pubmed_authors>Krajden M</pubmed_authors><pubmed_authors>Erb SR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission.</name><description>The goal of treating chronic hepatitis C virus (HCV) infection is sustained virologic response (SVR). There is concern that despite achieving SVR, replication-competent HCV may be sequestered at low levels within the liver and could theoretically reactivate with immunosuppression. We report transplantation of a HCV-seropositive liver donor, who achieved SVR, into a seronegative patient without HCV reactivation despite profound immunosuppression.Retrospective chart review.We present a 21-year-old male who was HCV seronegative and received a liver transplant from a donor who had been treated for HCV and achieved SVR. The liver recipient, despite developing severe acute graft rejection and undergoing intense immunosuppression with T cell-depleting antibodies, did not become HCV RNA-positive with a follow up period of 8 months. The recipient was HCV seronegative before transplant, but became HCV seropositive immediately posttransplant. The antibodies were undetectable after 97 days, in keeping with a passive antibody transmission or B lymphocyte transmission with the graft.To the best of our knowledge, this is the first reported case of an HCV seropositive liver allograft transplanted into an HCV-negative recipient who subsequently received intense immunosuppression. This case, therefore, is an encouraging and novel step in liver transplantation, and demonstrates that SVR may be closer to a true "cure" of HCV in the donor population and that, even in circumstances of very potent immunosuppression in the recipient, this SVR is sustained.</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Mar</publication><modification>2019-03-26T23:33:40Z</modification><creation>2019-03-26T23:33:40Z</creation></dates><accession>S-EPMC5912017</accession><cross_references><pubmed>29707618</pubmed><nct>NCT03112044</nct><doi>10.1097/TXD.0000000000000763 </doi></cross_references></HashMap>